Heterozygous Familial Hypercholesterolemia Clinical Trials

56 clinical trials for Heterozygous Familial Hypercholesterolemia across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) — RECRUITING · PHASE2
• A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease — RECRUITING · PHASE1
• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias — RECRUITING · PHASE1
• A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) — RECRUITING · PHASE3
• Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, with Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids) — RECRUITING · PHASE3
• "Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)" — RECRUITING · NA
• Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease — RECRUITING
• The ORIGIN-FH Study — RECRUITING · NA
• A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFECT OF AZD0780 ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA — RECRUITING · PHASE3
• A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia — RECRUITING · PHASE3
• Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia — RECRUITING
• OPEN-LABEL, PHASE LB, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY OF VERVE-102 ADMINISTERED TO PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR PREMATURE CORONARY ARTERY DISEASE WHO REQUIRE ADDITIONAL LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL — RECRUITING
• AN 8-WEEK OPEN-LABEL, SEQUENTIAL, REPEATED DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AIIROCUMAB IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA FOLLOWED BY AN EXTENSION PHASE — RECRUITING
• DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO CHARACTERIZE THE EFFICACY, SAFETY AND TOLERABLITY OF 24 WEEKS OF EVOLOCUMAB FOR LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LSL-C) REDUCTION, AS ADD-ON TO DIET AND LIPID-LOWERING THERAPY, IN PEDIATRIC SUBJECTS 10 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) — RECRUITING
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA — RECRUITING
• A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA — RECRUITING · PHASE3
• A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Medial Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). — TERMINATED · PHASE3
• Efficacy, Safety, and Tolerability of Ezetimibe and Simvastatin Taken Together, for the treatment of Adolescents With Heterozygous Familial Hypercholesterolemia — OTHER · PHASE3
• Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once daily (QD) for six months, compared with maximally tolerated Atorvastatin therapy alone, in subjects with heterozygous familial hypercholesterolemia. — COMPLETED · PHASE3
• A randomized study to assess efficacy and safety of Anaceptrapib when added to ongoing lipid-lowering therapy. — COMPLETED · PHASE3
• Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study — ACTIVE_NOT_RECRUITING
• Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (6 to less than 12 years) with heterozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-20) — TERMINATED · PHASE3
• Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial — TERMINATED · PHASE3
• Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) — COMPLETED · PHASE2
• Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy — NOT_YET_RECRUITING · PHASE1
• QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) — NOT_YET_RECRUITING · PHASE3
• A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease — COMPLETED · PHASE1
• Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C — COMPLETED · PHASE2
• A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). — COMPLETED · PHASE3
• Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C — COMPLETED · PHASE3
• Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction — COMPLETED · PHASE3
• Safety and Efficacy of IBI306 in HeFH Patients — COMPLETED · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK¿0616 IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA — COMPLETED · PHASE3
• A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) — COMPLETED · PHASE2
• Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders — COMPLETED · PHASE3
• Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia — OTHER · PHASE3
• RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF LIB003 IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS ON STABLE LIPID-LOWERING THERAPY REQUIRING ADDITIONAL LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION (LIBERATE-HEFH) — COMPLETED · PHASE3
• Long Term Safety Study of PRALUENT — TERMINATED · PHASE4
• TWO PART (DOUBLE-BLIND INCLISIRAN VERSUS PLACEBO [YEAR 1] FOLLOWED BY OPEN-LABEL INCLISIRAN [YEAR 2]) RANDOMIZED MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF INCLISIRAN IN ADOLESCENTS (12 TO LESS THAN 18 YEARS) WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND ELEVATED LDL-CHOLESTEROL (ORION-16) — COMPLETED
• Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) — COMPLETED · PHASE3
• Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) — COMPLETED · PHASE2
• Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy — COMPLETED · PHASE3
• Lp(a) and Aortic Valve Calcification — COMPLETED
• Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia — COMPLETED · NA
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY FOLLOWED BY AN OPEN LABEL TREATMENT PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA — COMPLETED
• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia — COMPLETED · PHASE3
• Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease — COMPLETED · PHASE3
• A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) — COMPLETED · PHASE3
• OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF EVOLOCUMAB FOR LDL-C REDUCTION, AS ADD-ON TO DIET AND LIPID-LOWERING THERAPY, IN PEDIATRIC SUBJECTS FROM 10 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) — COMPLETED

Refine this search